Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2014-05-22 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
审计报告
Audit Report / Information Classification · 95% confidence The document is titled as an "审计报告" (Audit Report) and contains detailed financial statements and notes, including audit opinions, accounting policies, and explanations related to the company's financials for the years 2012 and 2013. It includes extensive financial data, accounting methods, and audit firm references, indicating it is a standalone audit report rather than a full annual report or other filing. The length is substantial (15,000 characters), and the content is consistent with an Audit Report / Information filing. Therefore, the appropriate classification is AR (Audit Report / Information). FY 2013
2014-05-22 Chinese
北京国枫凯文律师事务所关于中源协和干细胞生物工程股份公司发行股份及支付现金购买资产并募集配套资金暨关联交易的法律意见书
M&A Activity Classification · 95% confidence The document is a detailed legal opinion letter from a law firm regarding a major asset restructuring involving issuance of shares and cash payment to purchase assets, along with related fundraising and connected transactions. It includes extensive legal analysis, transaction details, pricing, parties involved, and compliance with regulatory requirements. The document references Chinese securities laws, asset evaluation reports, audit reports, and regulatory approvals. It is not a financial report like an annual or interim report, nor is it a simple announcement or certification. It is a legal opinion specifically related to a major asset restructuring transaction, which is a form of M&A activity. Therefore, the document best fits the category of M&A Activity (TAR).
2014-05-22 Chinese
发行股份及支付现金购买资产并募集配套资金暨关联交易报告书（草案）
Capital/Financing Update Classification · 95% confidence The document is titled as a report on "发行股份及支付现金购买资产 并募集配套资金暨关联交易报告书" which translates to "Issuance of Shares and Payment of Cash to Purchase Assets and Raising Supporting Funds and Related Party Transaction Report". It is a detailed report (about 15,000 characters) describing a major asset acquisition transaction involving issuance of shares and cash payment, fundraising through share issuance, related party transactions, and includes extensive sections such as transaction overview, background, decision process, risk factors, financial information, legal opinions, and compliance. The document references regulatory approvals needed from the China Securities Regulatory Commission and the Shanghai Stock Exchange, and includes detailed financial and legal disclosures. This type of document is a formal report related to capital raising and asset acquisition activities, which fits the definition of a Capital/Financing Update (CAP) filing. It is not an announcement of a report publication, nor a full annual or interim report, nor a proxy or voting result. Therefore, the correct classification is CAP with high confidence.
2014-05-22 Chinese
备考盈利预测审核报告
Audit Report / Information Classification · 95% confidence The document is titled as a "备考盈利预测报告的编制说明" which translates to "Preparation Explanation of Pro Forma Profit Forecast Report". It contains detailed financial assumptions, accounting policies, and consolidation methods related to a profit forecast for the year 2014. The document includes extensive financial and accounting details, assumptions, and audit references, indicating it is a comprehensive financial forecast report rather than a brief announcement or a certification. It is not a full annual report (10-K) or interim report (IR) but rather a pro forma profit forecast report with audit review, which aligns with the category of Audit Report / Information (AR) as it includes audit opinions and accounting principles related to the forecast. It is not a simple announcement or regulatory filing, nor is it a presentation or earnings release. Therefore, the best fit is Audit Report / Information (AR). FY 2014
2014-05-22 Chinese
独立董事关于公司发行股份及支付现金购买资产并募集配套资金暨关联交易的独立意见
Capital/Financing Update Classification · 95% confidence The document is an independent opinion from independent directors regarding a company's issuance of shares and payment of cash to purchase assets and raise supporting funds, which is a major asset restructuring transaction. It references compliance with laws and regulations related to major asset restructuring, the fairness of the transaction price based on an asset appraisal report, and the need for shareholder and regulatory approval. The document is a formal opinion on a specific transaction and related materials, not a full financial report or earnings release. It is not a simple announcement but a detailed independent opinion on a major asset restructuring transaction, which fits the category of Capital/Financing Update (CAP) as it involves issuance of shares, payment for asset acquisition, and fundraising activities. The document length is 2035 characters, indicating it is a substantive opinion rather than a brief announcement or report publication notice.
2014-05-22 Chinese
拟收购上海执诚生物科技股份有限公司股权项目资产评估报告书
Capital/Financing Update Classification · 95% confidence The document is titled as an "资产评估报告书" which translates to "Asset Appraisal Report." It is a detailed report prepared by an appraisal company (Beijing Zhongtonghua Asset Appraisal Co., Ltd.) for Zhongyuan Xiehe Stem Cell Bioengineering Co., Ltd. regarding its proposed acquisition of equity in Shanghai Zhicheng Biotechnology Co., Ltd. The report includes detailed financial data, valuation methods, asset and liability breakdowns, and audit confirmations. It is not a general annual or quarterly report, nor is it an announcement or a brief summary. It is a standalone asset valuation report related to a capital transaction (acquisition). This fits best under the category of Capital/Financing Update (CAP), as it relates to a financing activity (equity acquisition) and contains an asset valuation report supporting that transaction. The document is substantive and detailed, not a mere announcement or certification, so it is not RPA or RNS. Therefore, the classification is CAP with high confidence.
2014-05-22 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.